Market Research Logo

Septic Shock - Pipeline Review, H2 2015

Septic Shock - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Septic Shock - Pipeline Review, H2 2015’, provides an overview of the Septic Shock’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Septic Shock, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Septic Shock and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Septic Shock
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Septic Shock and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Septic Shock products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Septic Shock pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Septic Shock
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Septic Shock pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Septic Shock Overview
Therapeutics Development
Pipeline Products for Septic Shock - Overview
Pipeline Products for Septic Shock - Comparative Analysis
Septic Shock - Therapeutics under Development by Companies
Septic Shock - Therapeutics under Investigation by Universities/Institutes
Septic Shock - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Septic Shock - Products under Development by Companies
Septic Shock - Products under Investigation by Universities/Institutes
Septic Shock - Companies Involved in Therapeutics Development
Adrenomed AG
Ferring International Center S.A.
Huons Co., Ltd.
InflaRx GmbH
Lixte Biotechnology Holdings, Inc.
Noxxon Pharma AG
Orion Oyj
Peptinov SAS
Pharmazz, Inc.
Spider Biotech
Takeda Pharmaceutical Company Limited
XImmune AB
Septic Shock - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
adrecizumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AM-12 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BC-1215 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BTZO-2 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
C-10 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HBN-1 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HBN-3 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HBN-4 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HU-003 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
IFX-1 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LB-100 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LB-102 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LB-1148 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
levosimendan - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MFH-147 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NOXD-20 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PMZ-2010 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Proteins to Inhibit Nuclear Factor Kappa B for Septic Shock - Drug Profile
Product Description
Mechanism of Action
R&D Progress
R-190 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SB-056 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
selepressin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Inhibit TNF for Septic Shock - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SP-14 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SP-9 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Synthetic Peptides for Inflammation and Infectious Disorders - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Septic Shock - Recent Pipeline Updates
Septic Shock - Dormant Projects
Septic Shock - Discontinued Products
Septic Shock - Product Development Milestones
Featured News & Press Releases
Oct 08, 2015: Tenax Therapeutics Provides Clinical Update for Lead Candidate Levosimendan
Jun 16, 2015: Tenax Therapeutics Highlights New Scientific Publication Regarding the Potential Mortality Benefits of Levosimendan in Septic Shock Patients
Feb 02, 2015: Leading BioSciences Receives FDA IND Clearance To Proceed With A Randomized, Multi-Center Phase 2 Clinical Trial Using LB1148 To Treat Septic Shock
Jan 02, 2013: Adrenomed Develops New Drug to Reduce Mortality from Septic Shock
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Septic Shock, H2 2015
Number of Products under Development for Septic Shock - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Comparative Analysis by Unknown Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd...1)
Products under Investigation by Universities/Institutes, H2 2015
Septic Shock - Pipeline by Adrenomed AG, H2 2015
Septic Shock - Pipeline by Ferring International Center S.A., H2 2015
Septic Shock - Pipeline by Huons Co., Ltd., H2 2015
Septic Shock - Pipeline by InflaRx GmbH, H2 2015
Septic Shock - Pipeline by Lixte Biotechnology Holdings, Inc., H2 2015
Septic Shock - Pipeline by Noxxon Pharma AG, H2 2015
Septic Shock - Pipeline by Orion Oyj, H2 2015
Septic Shock - Pipeline by Peptinov SAS, H2 2015
Septic Shock - Pipeline by Pharmazz, Inc., H2 2015
Septic Shock - Pipeline by Spider Biotech, H2 2015
Septic Shock - Pipeline by Takeda Pharmaceutical Company Limited, H2 2015
Septic Shock - Pipeline by XImmune AB, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Septic Shock Therapeutics - Recent Pipeline Updates, H2 2015
Septic Shock - Dormant Projects, H2 2015
Septic Shock - Discontinued Products, H2 2015
List of Figures
Number of Products under Development for Septic Shock, H2 2015
Number of Products under Development for Septic Shock - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Routes of Administration, H2 2015
Number of Products by Stage and Routes of Administration, H2 2015
Number of Products by Molecule Types, H2 2015
Number of Products by Stage and Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report